Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Asset Writedowns and Impairment (2016 - 2024)

Historic Asset Writedowns and Impairment for Coherus Oncology (CHRS) over the last 8 years, with Q4 2024 value amounting to $7.4 million.

  • Coherus Oncology's Asset Writedowns and Impairment fell 8471.73% to $7.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $14.1 million, marking a year-over-year decrease of 7311.22%. This contributed to the annual value of $14.1 million for FY2024, which is 7311.22% down from last year.
  • According to the latest figures from Q4 2024, Coherus Oncology's Asset Writedowns and Impairment is $7.4 million, which was down 8471.73% from $6.8 million recorded in Q1 2024.
  • Coherus Oncology's 5-year Asset Writedowns and Impairment high stood at $48.2 million for Q4 2023, and its period low was -$347000.0 during Q2 2023.
  • Its 4-year average for Asset Writedowns and Impairment is $11.6 million, with a median of $5.0 million in 2023.
  • In the last 5 years, Coherus Oncology's Asset Writedowns and Impairment plummeted by 9432.69% in 2023 and then skyrocketed by 10894.79% in 2024.
  • Over the past 4 years, Coherus Oncology's Asset Writedowns and Impairment (Quarter) stood at -$59000.0 in 2021, then soared by 44167.8% to $26.0 million in 2022, then skyrocketed by 85.5% to $48.2 million in 2023, then tumbled by 84.72% to $7.4 million in 2024.
  • Its last three reported values are $7.4 million in Q4 2024, $6.8 million for Q1 2024, and $48.2 million during Q4 2023.